All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should patients with myelofibrosis be transplanted before or after ruxolitinib failure?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MPN Hub spoke to Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Hamburg, DE. We asked, Should patients with myelofibrosis be transplanted before or after ruxolitinib failure?

Should patients with myelofibrosis be transplanted before or after ruxolitinib failure?

Ruxolitinib is a JAK1/2 inhibitor used to reduce spleen size and improve constitutional symptoms before transplantation. In this video, Kröger details when allogeneic stem cell transplantation should be performed in patients with myelofibrosis who have received treatment with ruxolitinib, based on available data from clinical trials.

Share: